(Q51963509)

English

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

scientific article published on 17 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

William C. Gruber

6

object named as

William C Gruber

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

author name string

Sigurveig Th Sigurdardottir

1

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Katrin Davidsdottir

2

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Vilhjalmur A Arason

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Olof Jonsdottir

4

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

France Laudat

5

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Ingileif Jonsdottir

7

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

language of work or name

0 references

publication date

17 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

26

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

33

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

4178-4186

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Impact of meningococcal C conjugate vaccine in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Control of pneumococcal disease in the United Kingdom--the start of a new era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.072

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.05.072

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/18606481

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51963509&oldid=1775335997"